8.23
+0.31(+3.91%)
Currency In USD
| Previous Close | 7.92 |
| Open | 8 |
| Day High | 8.59 |
| Day Low | 8 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 89,146 |
| Average Volume | 84,239 |
| Market Cap | 50.64M |
| PE | -0.61 |
| EPS | -13.54 |
| Moving Average 50 Days | 9.13 |
| Moving Average 200 Days | 9.5 |
| Change | 0.31 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $22.17 as of November 19, 2025 at a share price of $8.23. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $346.53 as of November 19, 2025 at a share price of $8.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodiumSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharm
Aligos Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, toda